Loading, please wait...
OCTOBER 2018 RESIDENT SEMINAR
Please join us for the first in our Resident Seminar series on Tuesday, October 9, 2018 at 1:00 PM. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series will focus on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor. For a map of the campus and directions, please click here »
|
|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 337
|
|
BLOCK 1
1:00 – 1:45 pm
|
Melatonin Receptor Agonists for the Prevention of ICU Delirium
Jennifer Voong, Pharm.D.
|
Cefepime for the Treatment of AmpC-producing Enterobacteriaceae
Anna Poston-Blahnik, Pharm.D.
|
Maintenance of opioid use disorder (OUD) using medication-assisted treatment (MAT) in primary care
Matthew Thomas, Pharm.D.
|
Azithromycin for Bronchiolitis Obliterans Syndrome in Lung Transplantation
Felicia Bartlett, Pharm.D.
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
BLOCK 2
1:55 – 2:40 pm
|
What is the Role for Oral Vasoactive Medications in Decreasing the Duration of IV Vasopressor Therapy?
Lauren Hoth, Pharm.D.
|
Utilization of MRSA Nasal Swabs to Tailor Antibiotic Therapy
Danielle Bozzardi, Pharm.D.
|
Anomalous epilepsy treatment: The role of cannabinoid products in contemporary medicine
Ashley Wellen, Pharm.D.
|
Treatment of Cancer-Associated Venous Thromboembolism
Emily Henningsen, Pharm.D.
|
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
|
BLOCK 3
2:50 – 3:35 pm
|
The Increasing Role of Ketamine Use in Acute and Chronic Pain Management
Cathy Grierson, Pharm.D.
|
An Update on Treatment of Clostridium difficile Infection
Erica Prost, Pharm.D.
|
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Artificial Heart Valves
Kelly Murphy, Pharm.D.
|
Cyclin 4/6 inhibitors: What is the role of the many drugs and combinations?
Elizabeth Diller, Pharm.D.
|
**NOTICE: "Anaomolous Epilepsy Treatment" by Ashley Wellen, Pharm.D. HAS MOVED to the second time block. Up to 0.75 hours of CE credit are available for each activity, for a maximum possible 2.25 hours if participants attend activities in each of the three time blocks.**
REGISTRATION INFORMATION
This event has mutliple concurrent sessions. To register, please select no more than ONE session per time block below. Registration is free, but is required in advance. Due to limited space, only those participants who register by 2:00 PM on Friday, October 5, 2018 will be able to request parking access on campus.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block.
SPECIAL ACCOMMODATIONS
If you require special accommodations, please notify us in advance. Every effort will be made to make accommodations where necessary.
Date: Oct 9, 2018 01:00 PM - 03:40 PM
Location: Academic & Research Building
CE Hours
9.00
Registration closes on Oct 16, 2018 12:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Requirements for CE Credit
In order to receive CPE Credit, participants are required to submit an evaluation for the session. Evaluations will be housed online at this web address for 14 days, after which time they will be closed.Immediately upon submission of the online evaluation, a report will be automatically generated and submitted to CPE Monitor using the NABP ePID and DOB stored in the participant's account profile. Participants should allow up to 48 hours for the credit to sync with their online NABP e-Profiles. Paper statements of credit are not provided. Only ONE session may be claimed per each time block - if multiple concurrent sessions are claimed, participants forfeit CPE credit for the activity.
Participants are responsible for ensuring accuracy of credit reporting and receipt of credit. It is recommended that participants log on and reivew the information under "my account" prior to submitting the evaluation. NABP ePID and date of birth must be accurate for credit reporting to occur. Evaluations cannot be reopened after 14 days.
Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
NOTES: Topics in concurrent time blocks are labeled as B1, B2, and B3 to designate Blocks 1, 2, and 3, respectively. To register, check the open box for a session for each of B1, B2, and B3. As a reminder, you may only claim credit for one session in each time block. When you are ready, click the green "Register Now" button at the bottom of the page to register for those sessions you have checked. If you are not already logged in, you will be asked to do so.
Pharmacy Students should NOT use this page to register. Students should CLICK HERE » to register.
Registration closes on Oct 16, 2018
at 12:00 AM
Registration closes on Oct 16, 2018
at 12:00 AM
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 1. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify risk factors for delirium and non pharmacologic methods to prevent ICU delirium
- Describe the relationship between melatonin and the sleep-wake cycle
- Evaluate the role of melatonin and melatonin receptor agonists in the prevention of ICU delirium
Speaker(s)/Author(s)
|
Jennifer Voong, Pharm.D.
|
Activity Number
0033-0000-18-079-L01-P
Date:
10/09/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 1. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify AmpC resistance in Enterobacteriaceae.
- Describe clinical evidence for the use of cefepime in AmpC-producing Enterobacteriaceae.
Speaker(s)/Author(s)
|
Anna Poston-Blahnik, Pharm.D.
|
Activity Number
0033-0000-18-075-L01-P
Date:
10/09/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 1. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify the recommendations for duration of long-term maintenance treatment of opioid use disorder.
- Describe the safety and efficacy of medication-assisted treatment in opioid use disorder.
Speaker(s)/Author(s)
|
Matthew Thomas, Pharm.D.
|
Activity Number
0033-0000-18-078-L01-P
Date:
10/09/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 1. Please ensure you claim credit for only one of these sessions.
Objectives
- Define bronchiolitis obliterans syndrome
- Describe the efficacy of azithromycin as treatment and prevention of BOS
Speaker(s)/Author(s)
|
Felicia Bartlett, Pharm.D.
|
Activity Number
0033-0000-18-065-L01-P
Date:
10/09/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 337
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 2. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify the consequences of prolonged IV vasopressor continuation.
- Define the ideal patient population for initiating oral vasoactive medications.
- Recall appropriate dosing regimens for oral vasoactive medications.
Speaker(s)/Author(s)
|
Lauren Hoth, Pharm.D.
|
Activity Number
0033-0000-18-076-L01-P
Date:
10/09/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 2. Please ensure you claim credit for only one of these sessions.
Objectives
- Recommend MRSA nasal screens to guide antibiotic therapy in the patients that would most benefit based on available literature.
- Utilize a patient’s MRSA nasal screen result to guide antibiotic recommendations when appropriate based on treatment indication and clinical context.
Speaker(s)/Author(s)
|
Danielle Bozzardi, Pharm.D.
|
Activity Number
0033-0000-18-066-L01-P
Date:
10/09/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
NOTE - THIS SESSION HAS MOVED AND IS NOW PART OF BLOCK 2!
This is one of four concurrent sessions as part of Session 2. Please ensure you claim credit for only one of these sessions.
Objectives
- Evaluate the appropriateness of cannabinoid therapy in epilepsy treatment.
- Describe the regulations required for cannabinoid distribution in Missouri.
Speaker(s)/Author(s)
|
Ashley Wellen, Pharm.D.
|
Activity Number
0033-0000-18-080-L01-P
Date:
10/09/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 2. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify factors that increase the risk of cancer-associated venous thromboembolism Identify factors that increase the risk of cancer-associated venous thromboembolism
- Interpret the results of recent trials comparing direct oral anticoagulants with low molecular weight heparins.
- Select an appropriate anticoagulation regimen for a patient with cancer-associated venous thromboembolism.
Speaker(s)/Author(s)
|
Emily Henningsen, Pharm.D.
|
Activity Number
0033-0000-18-068-L01-P
Date:
10/09/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 337
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 3. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify adverse effects of ketamine.
- Evaluate appropriate use of ketamine in acute pain based on current literature.
- Assess effectiveness of ketamine in the emergency department.
Speaker(s)/Author(s)
|
Cathy Grierson, Pharm.D.
|
Activity Number
0033-0000-18-073-L01-P
Date:
10/09/18
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 3. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify risk factors for developing C. difficile infection.
- Identify appropriate treatment regimens for C. difficile infection.
Speaker(s)/Author(s)
|
Erica Prost, Pharm.D.
|
Activity Number
0033-0000-18-081-L01-P
Date:
10/09/18
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 3. Please ensure you claim credit for only one of these sessions.
Objectives
- Explain the thromboembolic risk associated with artificial heart valves.
- Identify the appropriate use of DOACs in patients with artificial heart valves
Speaker(s)/Author(s)
|
Kelly Murphy, Pharm.D.
|
Activity Number
0033-0000-18-077-L01-P
Date:
10/09/18
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
NOTE - This is one of four concurrent sessions as part of Block 3. Please ensure you claim credit for only one of these sessions.
Objectives
- Identify the NCCN guideline recommended place in therapy for CDK 4/6 inhibitors.
- Compare and contrast the approved agents within the CDK 4/6 inhibitor class.
Speaker(s)/Author(s)
|
Elizabeth Diller, Pharm.D.
|
Activity Number
0033-0000-18-067-L01-P
Date:
10/09/18
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Location
ARB 337
Registration Closed
